180918-68-7|Trecetilide|(-)-4'-((S)-4-(Ethyl(6-fluoro-6-methylheptyl)amino)-1-hydroxybutyl)methanesulfonanilide|-范德生物科技公司

Trecetilide

NMR下载 COA and HPLC MSDS下载
names：
(-)-4'-((S)-4-(Ethyl(6-fluoro-6-methylheptyl)amino)-1-hydroxybutyl)methanesulfonanilide
CAS号：
180918-68-7
MDL Number：
MF(分子式)： C21H37FN2O3S MW(分子量)： 416.5964
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK20327-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(-)-4'-((S)-4-(Ethyl(6-fluoro-6-methylheptyl)amino)-1-hydroxybutyl)methanesulfonanilide
英文别名	Trecetilide
CAS号	180918-68-7
Inchi	InChI=1S/C21H37FN2O3S/c1-5-24(16-8-6-7-15-21(2,3)22)17-9-10-20(25)18-11-13-19(14-12-18)23-28(4,26)27/h11-14,20,23,25H,5-10,15-17H2,1-4H3/t20-/m0/s1
InchiKey	RPQUKWBLAHJOPX-FQEVSTJZSA-N
分子式 Formula	C21H37FN2O3S
分子量 Molecular Weight	416.5964
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Trecetilide(CAS:180918-68-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Trecetilide is a Class III anti-arrhythmia agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Buist SC, Hsu CY, Walters RR. Sensitive determination of a new antiarrhythmic agent, trecetilide, in plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr A. 1998 Dec 18;828(1-2):259-65. PubMed PMID: 9916311.

[2]Doggrell SA, Hancox JC. Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. Review. PubMed PMID: 15926871.

[3] Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 1999 Feb;10(2):307-17. Review. PubMed PMID: 10090237.

[4] Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 2000 Jan;15(1):41-53. Review. PubMed PMID: 10666660.

[5] Lee K, Park JY, Ryu PD, Kwon LS, Kim HY. IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23. Review. PubMed PMID: 15326913.

6: Humphrey SJ, Turman CN, Curry JT, Wheeler GJ. Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. J Cardiovasc Pharmacol. 2006 Mar;47(3):337-47. PubMed PMID: 16633074.7: Hester JB, Gibson JK, Buchanan LV, Cimini MG, Clark MA, Emmert DE, Glavanovich MA, Imbordino RJ, LeMay RJ, McMillan MW, Perricone SC, Squires DM, Walters RR. Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential. J Med Chem. 2001 Mar 29;44(7):1099-115. PubMed PMID: 11297456.8: Gupta AK, Maheshwari A, Thakur RK, Lokhandwala YY. Newer antiarrhythmic drugs. Indian Heart J. 2001 May-Jun;53(3):354-60. Review. PubMed PMID: 11516042.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开